World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Research Article
ISSN: 2583-6579
SJIF Impact Factor: 3.454
Year - 2024
Volume: 3; Issue: 1
Page: 122-136

HUMAN PAPILLOMAVIRUS (HPV) SCREENING AND VACCINATION: MOLECULAR INSIGHTS AND FUTURE CHALLENGES

Hamza Jabbar Jabour*[1], Hussein Ali Jamil[2] and Nebrass Faleh Chachain[3]

[1,2,3]College of Science, Mustansiriyah University, Baghdad – Iraq.

Article Received: 01 January 2024 | | Article Revised: 17 January 2024 | | Article Accepted: 27 February 2024

Corresponding Author: Hamza Jabbar Jabour
College of Science, Mustansiriyah University, Baghdad – Iraq.

ABSTRACT

The paper provides an overview of the existing context, problems in the way, and new paths in the fight against Human Papillomavirus (HPV). It addresses both the molecular biology as well as epidemiological aspects of HPV, screening methods and methods of therapy, types, and mechanisms of both current and novel HPV vaccines, and also discovers emerging technologies and strategies in HPV prevention. Socioeconomic challenges, co-infection factors, research black holes, and targeted healthcare approaches required in the fight against HPV are the main issues discussed. Under this concentration on cutting edge tactics of telemedicine incorporation, vaccine distribution balance, novel screening technologies, preventive education programs and investigation into vaccine virus survivability, stakeholders can aim on removing obstacles in the way of pure HPV-relating disease prevention and future outbreak control and even attempting the elimination of these diseases. Through collaboration between disciplines, involvement in the global debate and the adoption of a holistic approach, the fight against HPV and thereby for better health outcomes can be realistically achieved.

KEYWORDS: Human Papillomavirus (HPV), novel HPV vaccines, research black holes.

1. INTRODUCTION

The fight against Human Papillomavirus (HPV) as it relates to the frontline of the healthcare industry is a significant matter humanize the given sentence. Classified as the most commonly related with sexually transmissible infections, humans are mainly a catchment area for HPV virus species that come with different health implications. What makes some strains of HPV famous is the magnitude of their oncogenic (cancer causing) feature, it is those, which, as per the CEaseR Cervical cancer still remains a major cause of cancer related deaths among women worldwide.

Although the pandemic is being spread fast and has a disastrous effect, there still is an indication of hope represented by well-developed viral testing programs and the arrival of preventive vaccines. Screening methods such as the Pap smear and

HR-HPV DNA testing have become the crucial components of early detection and malignant changes prevention, allowing to detect and manage of precancerous stages at the beginning of the progression to the invasive cancer.[3-5] A move in the right direction would be followed by the vaccination introduction of HPV which came to embody a revolution in preventive medicine. These are by far the most recently approved preventive vaccines that target the most frequent strains linked to precancerous and cancerous conditions in the cervix. They have dramatically reduced the rates of infection as well as the incidence of abnormal cervical cells.[6]

Yet we can already sense that the moment to start eradicating HPV-related diseases is near, but not without several insurmountable hurdles to overcome, though. They include vaccination coverage, common challenges such as socioeconomic anomalies and cultural factors affecting HPV screening and vaccination services, and the updated molecular landscape of HPV.[7]

One aims to examine the molecular discoveries that form the base of our comprehension of HPV, assess the progress made on screening and vaccination policies and talk about the steps needed to be taken to come to a time and future in which HPV doesn't cause these diseases and become an issue of the past. Hence through this extensive research we are pursuing to unveil the path of the future effective in eliminating this virus as one of the universal health problems.

2. Molecular Biology of HPV

Genomic Structure

Human papilloma virus (HPV) is described as a small, round, double-stranded DNA with a genome that is encased in a protective capsid the viral DNA is arranged into early (E) and Late (L) regions after the expression of viral DNA in the course of the replicative cycle. The first portion of the virus's genome codifies the proteins necessary for viral replication and cell transformation, among other things (E1, E2, E4, E5, E6 and E7). In the late region, capsid proteins (L1 and L2) that are essential for the construction of the virions' structure are uncodified.[6]

Life Cycle and Pathogenesis *HPV has the ability to induce mucosal surface over or cutaneous cells. The first stage would be the virus to access the microbreaches and to bind on the basement membrane receptors. Then first replication in the basal layer of the epithelium will go. Infected cells which differentiate and migrate to the outer layer undergo genome amplification of the viral genome, utilizing it for late gene expression and formation of mature virions through which new infectious particles are released without causing cell lysis.[8]*

Oncogenic Mechanisms *HPV manifestation as a carcinogen relies more on the activities of E6 and E7 oncogene. These proteins can be activated by binding to and therefore, suppressing the pathways that involve the p53, Rb protein and so forth. Moreover, E6 maintains cell life by dislocating p53 and escaping apoptosis, and at the same time, E7 promotes Rb degradation, which results in unlimited cell replication. Continentally, these oncoproteins that are expressed for prolonged periods cannot be removed during differentiation and, as a result, these induced genomic instability in a fully differentiated cell type can generate cancerous growths particularly in the region of the cervix where epithelial cells undergo squamous and columnar transformation.[9,10]*

Viral Integration and Genetic Variability

The affection of HPV DNA in host genome is one of the main steps as a result of the progression from infection to cancer. This results in an interruption of the E2 that serves to control the E6 and E7 proteins. They are responsible for oncogenesis. With loss of function of E2, the expression of E6 and E7 can increase dynamically, and the host cells may be malignantly transformed continuously. Furthermore, the different HPV strains, as well as their diversity within the same type, allow certain HPV types to be more virulent, infectious, or tumorigenic than others.[11]

Host Immune Response and Evasion

HPV has gained the ability of working with immune system suppressor, as it results in the viral persistence and lesions. Exposure to UV light generates a low-level infection by limiting viral proteins expression at the basal layer of the epithelia and suppressing antigen presentation and stop DNA synthesis signals. This immune evasion is a fundamental way the virus restrains the body and develop chronic infections that are useful for tumor develop.[12]

Molecular Markers and Co-Factors

The escape to cancer involves molecular indicators such as viral load, warning-off status and the levels of expression of the E6/E7 oncoproteins. Host factors such as the genetic susceptibility to the development of the infection, hormonal influences and additional co-factors like smoking or the co-infection with the other sexually transmitted infections (STIs) bring forth theitional factors of the virus.[13]

3. Epidemiology of HPV

Prevalence and Incidence Rates

Human Papillomavirus, also known as HPV is one of the most frequently acquired sexually transmitted syndromes all over the globe. Age is an important consideration in HPV prevalence, whereby the highest rates are found mostly in sexually active teens and adults. Some incidents are a result of different types of sexual activities, while others are attributed to social norms and disciplines, and the availability of testing and vaccination programs.[14]

High-Risk Populations and Geographical Variance

Firstly, special attention should be paid to areas and individuals with a higher risk of contracting the disease. Moreover, because a virus tends to affect different areas of the world differently, adaptation to those specific situations will be vital. Some specific groups such as women and male homosexual men are predisposed more to HPV infections. Such patient populations include persons with multiple sexual partners, people with low immune system, and exploitation of various communities without medical services. Of the geographic distribution, HPV and the incidence regionally of specific HPV subtypes varies significantly, where depending on the level of vaccination coverage region whereas the subject of public health initiatives on HPV.[15]

HPV-Associated Cancers

HPV is etiologically related to many types of cancer and cervical cancer is the best off such kinds of cancer. Also, other cancers, which is related to HPV have been found such as anal, anus, penile, oropharyngeal, vulvar, and vaginal cancers.

These types of cancers have different distribution in different regions. Its distribution is dependent on the regions' types of HPV, behavioral risks, and the degree of use of preventative measures.[16]

Impact of Vaccination on Epidemiology

Implementing HPV vaccines has a profound effect on the epidemiology of the virus. The abatement of the high-risk HPV infections and the reduction in cervical precancerous infections among vaccine recipients have been reported in the literature, thus showing how HPV vaccines have helped prevent the disease. This influence on an individual vaccination interacts with the herd immunity as the first serves by protecting people as the latter prevents the circulation of the virus within the population.[17]

Gender and HPV

Even though HPV is commonly considered in the category of cervical cancer and woman health, it is acknowledged that men too get affected by HPV. The virus may cause genital wart as well as cancers in areas such as penis, anus and oropharynx in men. Epidemiological data of HPV-related diseases in men are still less graspable. Some difficulties exist in awareness, education, and prevention.[12,17,18]

Socioeconomic Factors

There is no denying the fact that economic situation does matter when it comes to the issue of HPV as well. The HPV rates and cancer incidence in the lower socioeconomic categories are usually found to be much higher because of the disparities in access to the preventive measures like screening, vaccination and treatment among others. Our whole health, as well as education, income, and access to healthcare services, have different levels of importance in this gap.[19]

Screening and Diagnostic Trends

The progress made on early diagnosis through testing techniques now allows a more accurate detection of HPV lesions. Since, diagnostic tests are developing and employed, the pattern of NHPV is being raised to better level of understanding. This fact makes great differences upon communal health approach, and the distribution of funds on the most useful supervision and treatment policies.[20]

Global Health Initiatives

As key agents of HPV epidemiology, international health organizations shape the epidemiology of HPV through their global health initiatives at the same time. Such initiatives may take the form of steps towards enhancing vaccine coverage, harmonizing the standards of screening, and developing outreach campaigns and educational materials about HPV and its connected risks.[21]

4. HPV Screening Methods

Cytological Testing (Pap Smear)

The Papanicolaou test, Pap smear for short, has occupied this essential role in a screening process for cervical cancer since the 1950's. The test is denting out cells from the cervix with the objective of looking for abnormalities in the morphology Although Cervical screening has discovered several cases and saved many lives from cervical cancer, it is not effective in

all patients due to a number of reasons, i.e., low sensitivity in detecting low grade lesions and high quality of cytology laboratory is necessary along with a regular follow up.[22]

Hpv Dna Testing

HPV DNA testing identifies the presence of high-risk HPV types in cervical cells samples, which has a higher sensitivity level but may be high cost. However, the HPV DNA test is more accurate than cytology alone for identifying CIN and cancer. It could serve as the main screening tool or in combination with the Pap test on a case to case basis depending on the current guidelines for screening and age group.[23]

Biomarkers and Molecular Assays

The progress in molecular biology has brought the tests which are based on looking for viral biomarkers like mRNA E6/E7 expression. Such active viral oncogenes present are actually associated with the active HPV infection within a person. The rest of the assays are concerned with the expression of p16INK4a, which holds the position of a surrogate marker of infections of the HPV that causes transformation.[24]

Co-Testing and Triage Strategies

To compare the two tests, we can the combined use of cytology and the HPV test, which can up the detection of precancerous lesions. In situation where tilted results are or fall within the normal range, triaging procedures that involve HPV typing, genotyping of specific HPV strains and repeat testing after the lapse of settled intervals can be employed in the determination of the right clinical management.[25]

Future Directions in Screening

Technology that is under the modern age, include next-generation sequencing and methylation analysis, has a big role to play in increasing the accuracy of screening. These methods do much more than that. It helps refining risk stratification and the prescription of personalized patient management plans. The screening programs are required to achieve scalability that is sensitivity, specificity, cost-effectiveness, and accessibility to get a satisfactory reduction of the HPV-related cancers. The actual screening method may be dictated by a resource assessment of a country and the population's health priorities. Doubts that accompany the exploration and knowledge of HPV biology come hand in hand with the development of new screening methods, and also lure further hopes for achieving more personalized and successful early detection techniques.[26,27]

Integration of Screening and Vaccination Data

The fusion of Screening and Vaccination Information is also important for controlling infectious diseases. Personalized care, which means having the vaccination status of HPV integrated with screening procedures, is a new unfolded element. Enlightenment about a patient’s immunization history would be vital for coordinating screening with the intervals and methods that best match patients’ vaccination status so that those with a lower risk of high-risk HPV infections could follow stricter screening guidelines.[28]

Self-Sampling for HPV Testing

In this case, self-sampling for the HPV DNA tests can revolutionize the reach because it will be easy to reach this population even the ones that live in an area with no accessible health services or cultural barriers facing common screening procedures. Data analysis has revealed that sample samples which are self-collected can be as efficient in detecting the occurrence of high-risk HPV, as when being clinician-collected.[29]

Reflex Testing

Reflex testing is a means whereby a sample that first was acquired for a cytology screening but is later sent for high-risk HPV test if the first screening result is abnormal. This approach the strategic management of patients susceptible to acquiring cervical cancer is vital because it delivers treatment for prognosis of those patients that are at higher risk.[30]

Risk-Based Screening

Risk factor screening relies on the own risk profile-including a person's age, sexual history, subsequent HPV vaccination, and prior screening results-being the determinants of the most suitable screening mode. This specific strategy will seek to maximize the advantages of screening, but with a simultaneous objective to prevent harmless interventions.[28]

Quality Assurance and Standardization

It is imperative that quality control be in place in the process of HPV screening; for results to be accurate the sample collection, storage and processing stages can affect outcome. Regular quality control is introduced to check that all the practices followed are similar among different locations and the findings are reliable.[31]

HPV screening landscape developments are overshadowed by technology innovations and more accurate knowledge concerning the virus's nature progression. The journey has begun in that the challenge will be in enacting these methods in a manner such that they are given accessibility to different healthcare systems and by so, being equitable.[32]

Table 1: Integrated Overview of HPV Screening and Outcomes Across Demographics and Regions

Screening Metric	Description	Data Source	Age Group	Gender	Vaccination Status	Geographic Region	Socioeconomic Status	Screening Outcome	Follow-Up Recommendations
HPV Prevalence	Percentage of the population testing positive for any HPV type.	National health surveys, research studies.	15-26, 27-45, 46-65, 65+	Female, Male, Other	Vaccinated, Unvaccinated	North America, Europe, Asia, Africa, Latin America, Oceania	Low, Middle, High	Positive for High-Risk HPV, Negative for HPV	Immediate colposcopy, Repeat screening in 1 year
Pap Smear Accuracy	Rate of true positive/negative results from cytology tests.	Clinical audits, quality control reports.	21-29, 30-65, 65+	Female	Not Applicable	Varies by healthcare facility	Varies by healthcare facility	Normal, ASC-US, LSIL, HSIL, Cancer	HPV testing, Biopsy, Routine screening interval
HPV Vaccine Impact	Reduction in high-risk HPV types since vaccine introduction.	Longitudinal studies, public health records.	9-14 (pre-vaccination), 15-26 (post-vaccination)	Female, Male	Received HPV vaccine (by type)	Worldwide by country	Not Applicable	Decline in HPV incidence rates	Not Applicable
Screening Coverage	Proportion of the eligible population receiving recommended screening.	National health databases, insurance claims.	Age-based on national guidelines	Female, Male (for anal cancer screening)	Not Applicable	Urban, Rural	Insured, Uninsured, Underinsured	Number/percentage screened	Increase outreach and education programs
Follow-Up Compliance	Percentage of individuals adhering to follow-up recommendations after abnormal screening.	Patient follow-up records, health system tracking.	As per screening outcome	Female, Male (as applicable)	Not Applicable	Varies by region and healthcare system access level	Varies by individual socioeconomic factors	Completed follow-up, Did not complete follow-up	Target interventions to improve compliance

5. HPV Vaccines: Types and Mechanisms

First-Generation Vaccines: Bivalent and Quadrivalent

The bivalent vaccine designed to tackle Only cervical cancer with HPV types 18 and 16 that are behind more than 70% of cervical cancer cases worldwide, is called Cervarix. The adjuvant also eventually leads to the production of antibodies that neutralize the virus by exposing the immune system to virus-like particles (VLPs).[33]

HPV vaccine (Gardasil) targets HPV types 6, 11, 16, and 18, known as Gardasil four-valent vaccine; this prevents cervical cancer and genital warts. The VLPs of these four HPV L1 capsid genes are used to mount a vigorous immune response that not only can protect individuals from infection but also help in the eradication of the virus.[34]

Second-Generation Vaccine: Nonavalent

The nonavalent vaccine (Gardasil 9) contains in fact the same HPV strains covered by the quadrivalent vaccine, plus other five which are highly dangerous.[31,33,45,52,58] Grandmaster vaccine in kind cover the extensive problems of HPV-related cancers.[35,36]

Immunogenicity and Cross-Protection

Immunogenicity of the HPV vaccines refers to the fact that they are able to bring a potent and long lasting immune response. It has been demonstrated that such vaccines stimulate the development of blocking antibodies to high levels which can keep their activity for many years after being vaccinated. Moreover, immunity mediated through the cross-protection mechanism is observed; antibodies produced against HPV type being vaccinated also provide some immunity against non-vaccine types closely related to the vaccines.[37]

Mechanism of Action

HPV vaccines offer the mechanism similar to the viral particle outer shell. These vaccines are composed of virus-like particles (VLPs) that do not bear viral DNA, the absence of this genetic material deems them incapable of causing real HPV infections or cancers. The immune system identifies VLPs is as an invader and responds by producing immune response which involves generating memory cells as well. These memory cells will have been prepared to immediately respond and neutralize HPV viruses in a real contact, these cells will be already imprinted with the information that they had encountered earlier.[38]

Duration of Protection and Booster Shots

Scientists are yet to come up with the duration that HPV vaccines provide protection through their studies. According to the recent findings, vaccinated people safeguard themselves from contracting the virus at least in 10 years with the studies still on how long the vaccine keeps the immunity. The rising query if the repeated shots required to ensure maintenance of long-term protection has created a huge debate.[39]

Therapeutic Vaccine Development

Not stopping only at preventative vaccines, there is a corresponding effort into therapeutic HPV vaccines, which would be capable of treating infections with HPV or diseases induced by it. Taken as a preventive measure, these vaccines are created

to enable the immune system to identify and kill cells infected with HPV that are associated with cancer progression or cancer that has existed over time.[40]

Vaccine Administration and Coverage Gaps

In order to protect the multitude of furry animals, vaccines against HPV contamination come in two- or three-dose courses. One of the factors that limits the effort of achieving very high coverage vaccination rates more specifically in countries with limited access to health care as well as vaccine hesitancy or inadequate public awareness about HPV risk is yet to be resolved.[41]

Addressing Vaccine Hesitancy

The problem of hesitancy among vaccine recipients is a key detriment for the total coverage of the HPV vaccines. For some of the populations, misinformation and doubts about the safety of vaccines are the reasons for low-vaccination rates Running the campaigns and educating the people where needed to solve these issues and increase public acceptance of HPV vaccines are vital.[42]

Table 2: Comprehensive Comparison of HPV Vaccines: Types, Mechanisms, and Impact.

Vaccine Attribute	Bivalent (Cervarix)	Quadrivalent (Gardasil)	Nonavalent (Gardasil 9)	Therapeutic Vaccines (In Development)
Target HPV Types	16, 18	6, 11, 16, 18	6, 11, 16, 18, 31, 33, 45, 52, 58	Various oncogenic HPV types
Mechanism of Action	VLPs inducing anti-HPV immune response	VLPs inducing anti-HPV immune response	VLPs inducing anti-HPV immune response	Activate immune system to target and destroy HPV-infected cells
Primary Prevention	Cervical cancer	Cervical cancer, Genital warts	Cervical cancer, Genital warts, Other HPV-associated cancers	Not applicable
Therapeutic Potential	None (prophylactic)	None (prophylactic)	None (prophylactic)	Treat existing infections or lesions
Immunization Schedule	Typically 2-3 doses	Typically 2-3 doses	Typically 2-3 doses	To be determined
Cross-Protection	Yes, against some related HPV types	Yes, against some related HPV types	Yes, against some related HPV types	Not applicable
Booster Requirement	Under study	Under study	Under study	To be determined
Age Group Recommended	Girls and women aged 9-45	Boys and girls aged 9-26, some guidelines up to age 45	Boys and girls aged 9-45	Varies based on clinical trials
Vaccine Efficacy	High efficacy against types 16 and 18 infections and related diseases	High efficacy against types 6, 11, 16, and 18 infections and related diseases	High efficacy against all included types infections and related diseases	Efficacy under study
Global Coverage Goals	Achieve high coverage in target age groups, particularly in low-income countries	Achieve high coverage in target age groups with a focus on both sexes	Achieve broad protection with higher-valency vaccine across diverse populations	Provide treatment options for those already infected or affected by HPV-associated diseases

6. Advances in HPV Screening and Vaccination

Novel Screening Technologies

The lately developed HPV screening technologies are quite novel and have made a great deal of innovation in order to solve the issues of detection of cervical precancerous and cancerous lesions. The technologies these devices use include HPV automated liquid-based cytology systems, molecular assays for HPV and point-of-care testing devices that provide quick results. This is done by increasing efficiency in early diagnosis and by smoothing out the process of screening the possible risk factors.[43]

Therapeutic Vaccine Development

The discovery of HPV vaccines for the purpose of treating and preventing cancers is a tremendous leap in the lives of those looking for an effective method to fight these diseases. These vaccines aim at triggering the immune system to identify and destroy HPV infections that are already existing or present antagonist lesions. Through the use of immune system, the hypothesis that therapeutic vaccines offer a probable way to treat HPV-related diseases except for prevention is generally true.[28,44]

Precision Medicine in HPV Management

The concept of precision medicine now is even expanding beyond HPV screening and treatment thanks to the development of risk profiles that fit individual cases. The applied method accounts for genetic, environmental, as well as lifestyle factors and customized treatment on this basis to improve health status. Targeting at high-risk individuals and making the treatments specific to the individuals are the most valued outcomes of precision medicine in terms of efficacy of control measure.[45]

Integration of Screening and Vaccination Data

Data analysis is, therefore, more complete with the integration of screening and vaccination data for proper control programs. Healthcare systems can close the loops in prevention through the connectivity of information on vaccines coverage, screening result and disease outcomes. This allows them to focus on where the gaps in the effort are and allocate of resources accurately to the point where the maximum impact can be yielded.[46]

Emerging Technologies for Vaccine Delivery

Research into new vaccine delivery systems, which consists of microneedle patches and mucosal vaccines, aims to lower down the barrier of HPV vaccines' accessibility and to boost the adherence to it. This helps and technologies demonstrate some advantages such easy-to-administer, reduced healthcare costs and increases to coverage among those who are disadvantaged.[47]

Table 3: Innovative Approaches in HPV Screening and Vaccination: Advancements, Impact, and Research Focus.

Advancements	Description	Impact	Implementation Status	Research Focus
Automated Liquid-Based Cytology Systems	Utilizes automated platforms for sample preparation and analysis, improving efficiency and standardization in cytological testing.	Enhances screening accuracy, reduces turnaround time, and minimizes human error in sample processing.	Widely adopted in developed healthcare settings, ongoing integration in resource-limited regions.	Optimization of slide preparation techniques, cost-effectiveness analysis, and quality control measures.
Molecular Assays for HPV Detection	Molecular tests that detect HPV DNA or RNA provide high sensitivity and specificity in identifying high-risk HPV types.	Enables early detection of HPV infections and associated lesions, leading to timely intervention and improved patient outcomes.	Increasing adoption in primary screening protocols, ongoing research on assay standardization and performance in diverse populations.	Development of multiplex assays, evaluation of novel biomarkers, and incorporation into screening algorithms.
Point-of-Care HPV Testing Devices	Portable devices for rapid HPV detection at the point of care, facilitating immediate results and decentralized screening.	Expands access to screening in remote or underserved areas, reduces follow-up delays, and enhances patient engagement.	Piloted in community-based settings and low-resource environments, ongoing validation for accuracy and reliability.	User acceptability studies, integration with telemedicine platforms, and cost-benefit analyses for widespread deployment.
Therapeutic HPV Vaccines	Therapeutic vaccines designed to treat existing HPV infections or precancerous lesions by activating the immune system against the virus.	Offers potential for targeted therapy, disease regression, and long-term immunity in individuals with persistent HPV infections.	Investigational phase with promising results in clinical trials, potential future integration into treatment protocols for HPV-related diseases.	Immunogenicity assessments, combination therapy studies, and optimization of dosing regimens for therapeutic efficacy.
Precision Medicine Applications	Utilizes individualized risk assessment and tailored interventions based on genetic, environmental, and lifestyle factors for optimized HPV management.	Enhances preventive strategies, treatment outcomes, and resource allocation by addressing specific patient needs and vulnerabilities.	Evolving towards personalized screening guidelines and treatment algorithms, integrating genomic data into clinical decision-making processes.	Population-based studies on risk prediction models, implementation challenges in diverse healthcare settings, and patient-centered outcomes research.

7. Future Challenges and Directions

Table 4: Future Focus in HPV Prevention and Management: Innovative Strategies and Collaborative Initiatives.

Challenge/ Direction	Description	Impact	Target Population	Multidisciplinary Approach
Telemedicine Integration	Incorporating telemedicine for remote screening, consultation, and follow-up care in HPV management.	Increases access to healthcare services, particularly in rural or isolated areas, enhancing patient engagement and continuity of care.	Underserved populations, individuals with limited mobility or access to healthcare facilities.	Collaboration between healthcare providers, technology experts, and policymakers to optimize telehealth platforms for HPV services.
Vaccine Equity Programs	Implementing targeted initiatives to improve vaccination coverage in marginalized	Reduces disparities in vaccine uptake and HPV-related disease burden, promoting health equity and population	Adolescents, young adults, underserved populations, minority groups.	Collaboration among public health agencies, community organizations, and advocacy groups to design culturally sensitive outreach programs

	communities and high-risk populations.	health outcomes.		and vaccine delivery strategies.
Innovative Screening Technologies	Advancing novel screening tools such as artificial intelligence algorithms and wearable devices for early detection of HPV infections.	Enhances screening accuracy, efficiency, and patient comfort, leading to timely interventions and improved outcomes.	General population, high-risk groups, individuals with limited access to traditional screening services.	Integration of technology experts, healthcare professionals, and data scientists to develop and validate innovative screening solutions for diverse healthcare settings.
Preventive Education Campaigns	Launching comprehensive educational campaigns to raise awareness about HPV, vaccination benefits, and screening importance.	Empowers individuals to make informed decisions about their health, fosters vaccine acceptance, and promotes proactive healthcare-seeking behaviors.	Adolescents, parents, healthcare providers, policymakers, educators.	Collaboration between public health agencies, schools, media outlets, and community influencers to develop culturally relevant and evidence-based educational materials and outreach strategies.
Research on Vaccine Durability	Conducting long-term studies to assess the durability of HPV vaccine-induced immunity and the need for booster doses.	Informs vaccination guidelines, identifies optimal dosing regimens, and guides future immunization strategies for sustained protection against HPV infections.	Vaccinated populations across different age groups, high-risk individuals, immunocompromised individuals.	Collaboration among vaccine researchers, epidemiologists, immunologists, and public health experts to monitor vaccine efficacy over time and inform evidence-based vaccination policies.

CONCLUSION

In the end, the environment regarding which natural science area moves the world is getting changed as fast as improvements are made to the screening technology, development of the vaccine, and personalized medicine. For example, exploration of social-economic obstacles, relation between co-infections, and knowledge gapp especially in the research field ensure the prevailing role of innovation and cooperation in curbing HPV-linked diseases. By integrating the telemedicine, the equity programs, the innovative screening tools, the education campaigns and the research of the vaccine durability we can counter these problems and furthermore the cause where HPV-associated morbidity and mortality are significantly declined. By combining through diverse approaches and being involved in global advocacy, together we can make a better world where the effective HPV prevention techniques afterwards will be an improved public health situation with the HPV disease eventually eliminated.

REFERENCES

1. Soheili M, Keyvani H, Soheili M, Nasseri S. Human papilloma virus: A review study of epidemiology, carcinogenesis, diagnostic methods, and treatment of all HPV-related cancers. Med J Islam Repub Iran, 2021; 35: 65.
2. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine, 2013; 31 Suppl 8(0 8): I1-31.
3. Al-Jindeel TJ, Al-Karawi AS, Kready HO, Mohammed M. Prevalence of COVID-19 virus infection in asymptomatic volunteers in Baghdad city/Iraq during 2021. International Journal of Health Sciences, 2021; 6(S2): 5524-30.
4. Lorenzi AT, Syrjänen KJ, Longatto-Filho A. Human papillomavirus (HPV) screening and cervical cancer burden. A Brazilian perspective. Virology Journal, 2015; 12(1): 112.

5. Zhu Y, Wang Y, Hirschhorn J, Welsh KJ, Zhao Z, Davis MR, et al. Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination. Adv Clin Chem, 2017; 81: 135-92.
6. Pathak P, Pajai S, Kesharwani H. A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer. Cureus, 2022; 14(9): e28710.
7. Ebrahimi N, Yousefi Z, Khosravi G, Malayeri FE, Golabi M, Askarzadeh M, et al. Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective. Front Immunol, 2023; 14: 1150238.
8. Horvath CA, Boulet GA, Renoux VM, Delvenne PO, Bogers JP. Mechanisms of cell entry by human papillomaviruses: an overview. Virol J., 2010; 7: 11.
9. Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat, 2005; 37(6): 319-24.
10. Al-Karawi AS, Abid FM, Mustafa A, Abdulla M. Revealing the Urinary Microbiota in Prostate Cancer: A Comprehensive Review Unveiling Insights into Pathogenesis and Clinical Application. Al-Salam Journal for Medical Science, 2024; 3(1): 45-54.
11. Pešut E, Đukić A, Lulić L, Skelin J, Šimić I, Milutin Gašperov N, et al. Human Papillomaviruses-Associated Cancers: An Update of Current Knowledge. Viruses, 2021; 13(11).
12. Song D, Li H, Li H, Dai J. Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer. Oncol Lett, 2015; 10(2): 600-6.
13. Tomaić V. Functional Roles of E6 and E7 Oncoproteins in HPV-Induced Malignancies at Diverse Anatomical Sites. Cancers (Basel), 2016; 8(10).
14. Humans IWGotEoCRt. Human Papillomavirus (HPV) Infection. Human Papillomaviruses: International Agency for Research on Cancer, 2007.
15. Hui EK. Reasons for the increase in emerging and re-emerging viral infectious diseases. Microbes Infect, 2006; 8(3): 905-16.
16. Dabán-López P, Fernández-Martínez NF, Petrova D, Rodríguez-Barranco M, Jiménez-Moleón JJ, Gutierrez J, et al. Epidemiology of human papillomavirus-associated anogenital cancers in Granada: a three-decade population-based study. Front Public Health, 2023; 11: 1205170.
17. Luttjeboer J, Simons J, Westra T, Wilschut J, Boersma C, Postma M, et al. An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands. Infect Dis Ther, 2023; 12(8): 2135-45.
18. MOHAMMED M, Mousa D, Tareq Jafaar Al-Jindeel H, Al-Karawi S. Latent and reactivation Cytomegalovirus (CMV) infection can cause severe fetal sequelae despite pre-conceptional immunity.
19. Kops NL, Horvath JDC, Bessel M, Souza FMA, Benzaken AS, Pereira GFM, et al. The impact of socioeconomic status on HPV infection among young Brazilians in a nationwide multicenter study. Prev Med Rep, 2021; 21: 101301.
20. Gradíssimo A, Burk RD. Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention. Expert Rev Mol Diagn, 2017; 17(4): 379-91.
21. Milano G, Guarducci G, Nante N, Montomoli E, Manini I. Human Papillomavirus Epidemiology and Prevention: Is There Still a Gender Gap? Vaccines (Basel), 2023; 11(6).

22. Sachan PL, Singh M, Patel ML, Sachan R. A Study on Cervical Cancer Screening Using Pap Smear Test and Clinical Correlation. Asia Pac J Oncol Nurs, 2018; 5(3): 337-41.
23. Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, Zappacosta R, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol, 2011; 49(7): 2643-50.
24. Sharma B, Lakhanpal V, Singh K, Oberoi L, Bedi PK, Devi P. Evaluation of HPV E6/E7 mRNA Detection in Clinically Suspected Cases of Cervical Cancer with Abnormal Cytology: Time to Upgrade the Screening Protocols. J Lab Physicians, 2022; 14(3): 336-42.
25. Gilham C, Sargent A, Kitchener HC, Peto J. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT. Health Technol Assess, 2019; 23(28): 1-44.
26. Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, et al. Next-Generation Sequencing Technology: Current Trends and Advancements. Biology, 2023; 12(7): 997.
27. Qin D. Next-generation sequencing and its clinical application. Cancer Biol Med, 2019; 16(1): 4-10.
28. Charde SH, Warbhe RA. Human Papillomavirus Prevention by Vaccination: A Review Article. Cureus, 2022; 14(10): e30037.
29. Dartibale CB, Prado GC, Carobeli LR, Meirelles LEF, Damke G, Damke E, et al. Recent HPV self-sampling use for cervical cancer screening in Latin America and Caribbean: a systematic review. Front Oncol, 2022; 12: 948471.
30. Loopik DL, Melchers W, Vedder J, van den Brule A, Massuger L, Bekkers R, et al. Reflex cytology for triage of high-risk human papillomavirus positive self-sampled material in cervical cancer screening: a prospective cohort study. Bjog, 2020; 127(13): 1656-63.
31. Cuschieri K, Fellner MD, Arroyo Mühr LS, Padalko E, Correa RM, Dillner J, et al. Quality assurance in human papillomavirus testing for primary cervical screening. Int J Gynecol Cancer, 2023; 33(5): 802-11.
32. Osei EA. Innovations in healthcare delivery: Human papilloma virus self sampling diagnostics and participatory innovations for CCS. Cancer Med, 2023; 12(14): 15544-51.
33. Szarewski A. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert Rev Vaccines, 2012; 11(6): 645-57.
34. Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs, 2006; 66(9): 1263-71; discussion 72-3.
35. Paz-Zulueta M, Álvarez-Paredes L, Rodríguez Díaz JC, Parás-Bravo P, Andrada Becerra ME, Rodríguez Ingelmo JM, et al. Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions. BMC Cancer, 2018; 18(1): 112.
36. Mohammed ZJ, Sharba MM, Mohammed AA. The Effect of cigarette smoking on haematological parameters in healthy college students in the capital, baghdad. European Journal of Molecular & Clinical Medicine.
37. Pinto LA, Dillner J, Beddows S, Unger ER. Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine, 2018; 36(32 Pt A): 4792-9.
38. Wang JW, Roden RB. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines, 2013; 12(2): 129-41.

39. Williamson AL. Recent Developments in Human Papillomavirus (HPV) Vaccinology. Viruses, 2023; 15(7).
40. Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth, II. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res, 2018; 5: 46-58.
41. Bloem P, Ogbuanu I. Vaccination to prevent human papillomavirus infections: From promise to practice. PLoS Med, 2017; 14(6): e1002325.
42. Milondzo T, Meyer JC, Dochez C, Burnett RJ. Human Papillomavirus Vaccine Hesitancy Highly Evident among Caregivers of Girls Attending South African Private Schools. Vaccines (Basel), 2022; 10(4).
43. Kundrod KA, Smith CA, Hunt B, Schwarz RA, Schmeler K, Richards-Kortum R. Advances in technologies for cervical cancer detection in low-resource settings. Expert Rev Mol Diagn, 2019; 19(8): 695-714.
44. Alajeeli FS, Al-Karawi AS, Ali MM. The Immunological Significance of Medicinal Plants in Disease Control and Prevention in Humans. Al-Salam Journal for Medical Science, 2023; 2(2): 13-9.
45. Yang J, Nittala MR, Velazquez AE, Buddala V, Vijayakumar S. An Overview of the Use of Precision Population Medicine in Cancer Care: First of a Series. Cureus, 2023; 15(4): e37889.
46. Rahmadhan M, Handayani PW. Challenges of vaccination information system implementation: A systematic literature review. Hum Vaccin Immunother, 2023; 19(2): 2257054.
47. Menon I, Bagwe P, Gomes KB, Bajaj L, Gala R, Uddin MN, et al. Microneedles: A New Generation Vaccine Delivery System. Micromachines (Basel), 2021; 12(4).